실적분석 2026년 8월 3일

BWX Technologies ($BWXT) Q2 2026 Earnings Analysis — Adjusted EPS Beats but Stock Drops After-Hours Despite Guidance Raise

Earnings Scorecard

Revenue: $902 million (+18% YoY, estimate $904 million) ❌ Miss

EPS: Adjusted $1.07 (estimate $1.04) ✅ Beat

Guidance: Raised — 2026 adjusted EPS $4.70–$4.80, adjusted EBITDA $662M–$672M, free cash flow $345M–$360M

Stock Reaction: After-hours -4.00% ($166.84) — as of 08-04 06:04 Korea time

The Positives

Commercial segment surge: Revenue $303 million, up 72% YoY

Adjusted EPS beat: $1.07 topped the $1.04 consensus

Full-year guidance raised across the board: Both adjusted earnings and free cash flow outlook lifted

BWX Technologies ($BWXT) is a manufacturing and engineering company that supplies U.S. nuclear security and commercial nuclear components and services. Q2 2026 consolidated revenue came in at $902 million, up 18% from $764 million a year earlier, while adjusted EPS of $1.07 topped the analyst consensus of $1.04. GAAP diluted EPS was $0.97, and net income attributable to common shareholders was $89.01 million (total net income $89.10 million).

The growth engine was the commercial segment. Commercial revenue climbed to $303 million, up 72% YoY, with operating income of $24.3 million, a 254% surge. The result reflects the combined effect of expanding commercial nuclear components, field services, fuel handling, and medical operations, along with the contribution from Kinectrics. Reflecting solid first-half results and the contribution from the recently completed acquisition of the Precision Components Group on July 1, the company raised its full-year 2026 guidance across the board and announced the divestiture of its medical business, saying it will focus resources on its core nuclear security and commercial nuclear operations.

The Negatives

Revenue slightly below estimate: $902 million vs. $904 million consensus

Government segment profit softens: Operating income down 3% YoY

Free cash flow shrinks: $115 million in the quarter, down 9% YoY

Revenue came in just shy of the $904 million consensus. While growth was strong, on a "versus expectations" basis it leaves something to be desired. The government segment posted revenue of $601 million, up 2%, but operating income of $106 million fell 3% YoY. Management explained that fewer favorable contract adjustments and a less favorable product mix versus the year-ago quarter were the drivers.

Free cash flow of $115 million was down 9% from $126 million a year earlier. Operating cash flow edged down slightly, and capex rose as growth investments were concentrated in the commercial segment. Q2 new orders of $649 million also fell sharply from $1.64 billion a year ago, largely due to a tough comparison with a high base last year. That said, the backlog stands at $8.40 billion, still robust versus $6.02 billion a year earlier.

What Management Said

Management characterized Q2 results as having exceeded the company's own expectations, highlighted solid execution across all businesses, and pointed to standout performance in the commercial segment and free cash flow generation. Stressing that demand for new nuclear solutions is very deep and broad, the CEO reiterated the strategy of divesting the medical business to concentrate resources on nuclear security and commercial nuclear, while continuing investments to expand U.S. commercial manufacturing capacity and modernize facilities.

The rationale given for the guidance raise was solid first-half results, the contribution from the recently completed Precision Components Group acquisition, and confidence in execution for the remainder of the year. The tone was broadly confident, but the market appears to have moved into a phase where, with much of the growth story already priced into the shares, investors are applying a tougher lens to "how much further can it accelerate."

Market Reaction and What to Watch Next

The stock rallied during the regular session on earnings optimism and closed higher, then turned lower after-hours immediately after the release as profit-taking set in. Despite the adjusted EPS beat and full-year guidance raise, the modest revenue miss, softer government segment profit, and decline in free cash flow kept the print from reading as a "clean" beat. With valuation elevated on the nuclear theme, the setup is one where strong results without an additional upside catalyst make a pullback easier.

Watch how the terms and timing of the medical business divestiture translate into the post-deal earnings structure.

Monitor how quickly the Precision Components Group acquisition contributes to revenue and margins from Q3 onward, and the magnitude of any synergies.

Check whether the government segment's contract mix and margins recover, and whether commercial segment growth continues while absorbing the capex burden.